Article

Simultaneous Targeting of XPO1 and BCL2 as an Effective Treatment Strategy for Double-Hit Lymphoma

2019-07-01

Abstract excerpt

Double-hit lymphoma (DHL) is among the most aggressive and chemoresistant lymphoma subtypes. DHLs carry genomic abnormalities in MYC, BCL2 and/or BCL6 oncogenes. Due to simultaneous overexpression of these driver oncogenes, DHLs are highly resistant to the frontline therapies. Most DHLs overexpress both MYC and BCL2 driver oncogenes concurrently. We reasoned that simultaneous suppression of the two driver oncogene...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 54c1c2e1-750a-51e5-8b68-f0677cf96707
DOI: 10.1101/688093

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Simultaneous Targeting of XPO1 and BCL2 as an Effective Treatment Strategy for Double-Hit LymphomaDOI 10.1101/688093Read

Drug therapy for double-hit lymphomaSemantic proximity Read

Double-hit lymphomas: current paradigms and novel treatment approaches.Semantic proximity Read

Altered pathways and targeted therapy in double hit lymphomaSemantic proximity Read

Emerging Strategies in Treating Double Hit Lymphomas.Semantic proximity Read

Synergistic effects of XPO1 inhibitors combined with CD19 CAR-T cells in TP53-mutated DLBCL.Semantic proximity Read

Double hit lymphoma: from biology to therapeutic implications.Semantic proximity Read

Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?Semantic proximity Read

Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.Semantic proximity Read

Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistanceSemantic proximity Read

CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 RearrangementsSemantic proximity Read

Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related LymphomaSemantic proximity Read

Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypesSemantic proximity Read